Kyntra Bio, Inc.
corporate_fare Company Profile
Kyntra Bio, Inc. (NASDAQ:KYNB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for KYNB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for KYNB spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Kyntra Bio 10-Q: $44.1M Cash Into 2028, FG-3246 Killed, NovaQuest Cap Cut to $15M
- Kyntra Bio Posts $0.04 Q3 EPS, Kills FG-3246, Ties Phase 3 to New Financing
- Kyntra Bio Scraps FG-3246 Phase 2 Trial, Posts $0.2M Q3 Profit
- Nasdaq Moves to Delist Kyntra Bio; Company Seeks Hearing to Stay Suspension
- Kyntra Bio Slashes Royalty Financing Obligation by $60M with $42.6M Upfront Payment
Financial Snapshot
Short Interest & Short Volume
4.68 days to coverFINRA reported short interest of 95,811 shares in KYNB as of the October 30, 2026 settlement, a 0.9% increase from the prior period — about 4.7 days to cover at its recent average daily volume. On November 20, 2026, 34.3% of KYNB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.